Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/12/2025

Diagnostic Approach to Reverse Halo Sign in HIV Patients

Primary Diagnostic Considerations

  • In HIV patients with advanced infection, particularly those with CD4+ counts <100 cells/µL, history of other AIDS-defining opportunistic infections, and not receiving antiretroviral therapy, invasive fungal infections are a primary concern 1
  • HIV-infected persons have an increased incidence of TB, and the presentation can be varied 2

Immediate Management Algorithm

  • Patients with CD4+ counts <100 cells/µL and history of AIDS-defining OIs are at highest risk for invasive aspergillosis 1
  • Voriconazole is the recommended treatment for invasive aspergillosis 1
  • Amphotericin B (lipid formulation preferred) is first-line therapy for suspected mucormycosis 5

Concurrent TB Evaluation and Coverage

  • Dual therapy for both bacterial pneumonia and TB is appropriate for patients where both diagnoses are considerations 6
  • If TB is strongly suspected based on clinical presentation or RHS morphology (nodules in wall), initiate standard four-drug TB therapy immediately 2

Diagnostic Workup

  • Blood cultures should be obtained before starting antibiotics due to increased incidence of bacteremia in HIV patients 3
  • Histological evidence of tissue invasion by hyphae with positive culture represents definite diagnosis 1

Critical Pitfalls to Avoid

  • Fluoroquinolones should be used with caution in patients in whom TB is suspected but is not being treated with concurrent standard four-drug TB therapy 2
  • Never use macrolide monotherapy for bacterial pneumonia in HIV patients due to increased risk of drug-resistant Streptococcus pneumoniae 3

Additional Considerations

  • Initiate or optimize antiretroviral therapy to improve immune function and reduce risk of future opportunistic infections 4
  • Consider potential drug interactions between antifungals and antiretroviral agents, particularly protease inhibitors 5